Gambro settlement
This article was originally published in The Gray Sheet
Executive Summary
Dialysis firm will pay $355 mil. to settle charges related to renal care Medicare billing practices, upon entering into a five-year corporate integrity agreement. The deal finalizes a July preliminary understanding with the Department of Justice (1"The Gray Sheet" July 26, 2004, p. 13). Funds for the settlement were set aside in Q2...
You may also be interested in...
Gambro Settles Medicare Billing Suit, Signs Corporate Integrity Agreement
Gambro Healthcare US will record a second quarter charge of $355 mil. to cover a definitive settlement agreement with the U.S. Department of Justice, expected to be completed by December
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.